These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 20140868)

  • 1. [Histone deacetylase inhibitors as therapeutic agents for polyglutamine disorders].
    Jiang H; Jia D; Tang B
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2010 Feb; 27(1):52-5. PubMed ID: 20140868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histone deacetylase inhibitors as therapeutics for polyglutamine disorders.
    Butler R; Bates GP
    Nat Rev Neurosci; 2006 Oct; 7(10):784-96. PubMed ID: 16988654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transcriptional dysregulation in Huntington's disease: The role of histone deacetylases.
    Sharma S; Taliyan R
    Pharmacol Res; 2015 Oct; 100():157-69. PubMed ID: 26254871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms of disease: Histone modifications in Huntington's disease.
    Sadri-Vakili G; Cha JH
    Nat Clin Pract Neurol; 2006 Jun; 2(6):330-8. PubMed ID: 16932577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila.
    Steffan JS; Bodai L; Pallos J; Poelman M; McCampbell A; Apostol BL; Kazantsev A; Schmidt E; Zhu YZ; Greenwald M; Kurokawa R; Housman DE; Jackson GR; Marsh JL; Thompson LM
    Nature; 2001 Oct; 413(6857):739-43. PubMed ID: 11607033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulating epigenetic HAT activity for reinstating acetylation homeostasis: A promising therapeutic strategy for neurological disorders.
    Ganai SA; Banday S; Farooq Z; Altaf M
    Pharmacol Ther; 2016 Oct; 166():106-22. PubMed ID: 27411674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acetylation of proteins as novel target for antitumor therapy: review article.
    Di Gennaro E; Bruzzese F; Caraglia M; Abruzzese A; Budillon A
    Amino Acids; 2004 Jul; 26(4):435-41. PubMed ID: 15290351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Assay for inhibitory activity of histone deacetylase].
    Yoshida M
    Gan To Kagaku Ryoho; 2004 Apr; 31(4):507-11. PubMed ID: 15114691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histone deacetylase inhibitors: a novel therapeutic approach to Huntington's disease (complex mechanism of neuronal death).
    Sadri-Vakili G; Cha JH
    Curr Alzheimer Res; 2006 Sep; 3(4):403-8. PubMed ID: 17017871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is there a future for histone deacetylase inhibitors in the pharmacotherapy of psychiatric disorders?
    Grayson DR; Kundakovic M; Sharma RP
    Mol Pharmacol; 2010 Feb; 77(2):126-35. PubMed ID: 19917878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histone deacetylase inhibitors: biology and mechanism of action.
    Mehnert JM; Kelly WK
    Cancer J; 2007; 13(1):23-9. PubMed ID: 17464243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protein deacetylases: enzymes with functional diversity as novel therapeutic targets.
    Yoshida M; Shimazu T; Matsuyama A
    Prog Cell Cycle Res; 2003; 5():269-78. PubMed ID: 14593721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospects: histone deacetylase inhibitors.
    Dokmanovic M; Marks PA
    J Cell Biochem; 2005 Oct; 96(2):293-304. PubMed ID: 16088937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HATs off to Hop: recruitment of a class I histone deacetylase incriminates a novel transcriptional pathway that opposes cardiac hypertrophy.
    Hamamori Y; Schneider MD
    J Clin Invest; 2003 Sep; 112(6):824-6. PubMed ID: 12975465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histone deacetylase inhibitors and their potential role in inflammatory bowel diseases.
    Edwards AJ; Pender SL
    Biochem Soc Trans; 2011 Aug; 39(4):1092-5. PubMed ID: 21787354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention.
    Yang XJ; Seto E
    Oncogene; 2007 Aug; 26(37):5310-8. PubMed ID: 17694074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetic regulation of airway inflammation.
    Adcock IM; Tsaprouni L; Bhavsar P; Ito K
    Curr Opin Immunol; 2007 Dec; 19(6):694-700. PubMed ID: 17720468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expanded polyglutamine peptides disrupt EGF receptor signaling and glutamate transporter expression in Drosophila.
    Liévens JC; Rival T; Iché M; Chneiweiss H; Birman S
    Hum Mol Genet; 2005 Mar; 14(5):713-24. PubMed ID: 15677486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent advances in the discovery of small molecule histone deacetylase inhibitors.
    Remiszewski SW
    Curr Opin Drug Discov Devel; 2002 Jul; 5(4):487-99. PubMed ID: 12197307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histone deacetylases, transcriptional control, and cancer.
    Cress WD; Seto E
    J Cell Physiol; 2000 Jul; 184(1):1-16. PubMed ID: 10825229
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.